Valuation: PharmaEngine, Inc.

Market Cap 9.28B 289M 252M 233M 216M 406M 27.74B 413M 2.78B 1.09B 13.58B 1.08B 1.06B 46.77B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 4.61B 143M 125M 116M 107M 201M 13.77B 205M 1.38B 542M 6.74B 538M 526M 23.21B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.82%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-2.12%
1 week+1.57%
Current month+5.90%
1 month+12.15%
3 months+10.24%
6 months-7.05%
Current year-8.24%
1 week 62.5
Extreme 62.5
67.7
1 month 55.8
Extreme 55.8
67.7
Current year 53
Extreme 53
74
1 year 53
Extreme 53
81.5
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 13/06/2019
Director/Board Member - 15/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.12%+1.57%-17.07%-24.09% 295M
-1.05%+1.39%+3.15%+6.98% 50.61B
+0.84%-2.96%+381.67%+593.23% 39.11B
+0.16%-0.43%+29.49%-6.22% 34.64B
+1.06%-0.42%+22.03%+56.71% 33.79B
-1.31%-1.76%+1.59%+27.01% 26.89B
+1.01%+0.21% - - 16.47B
+1.64%-1.49%+67.98%+121.27% 15.14B
-0.72%+0.12%+14.69%+16.95% 13.85B
+1.54%-0.30%+12.51%-31.69% 12.72B
Average +0.12%-1.27%+57.34%+84.46% 24.35B
Weighted average by Cap. +0.18%-1.14%+80.52%+121.74%

Financials

2024 2025
Net sales 2.52B 78.51M 68.61M 63.42M 58.6M 110M 7.54B 112M 756M 297M 3.69B 295M 288M 12.71B 911M 28.36M 24.78M 22.91M 21.16M 39.86M 2.72B 40.58M 273M 107M 1.33B 107M 104M 4.59B
Net income 1.75B 54.48M 47.61M 44.01M 40.66M 76.57M 5.23B 77.96M 525M 206M 2.56B 205M 200M 8.82B 388M 12.06M 10.54M 9.74M 9M 16.95M 1.16B 17.26M 116M 45.59M 567M 45.3M 44.3M 1.95B
Net Debt -3.85B -120M -105M -96.86M -89.49M -169M -11.52B -172M -1.16B -453M -5.64B -450M -440M -19.42B -4.67B -145M -127M -117M -109M -204M -13.97B -208M -1.4B -550M -6.84B -546M -534M -23.55B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
14/07/26 NT$64.60 -2.12% 880,657
13/07/26 NT$66.00 +2.33% 2,324,866
09/07/26 NT$64.50 +1.42% 964,015
08/07/26 NT$63.60 -0.31% 1,726,094
07/07/26 NT$63.80 +0.31% 658,928
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock